NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00781-5238-01 | 00781-5238 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 31, 2007 | Aug. 31, 2007 | In Use |
00781-5238-06 | 00781-5238 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 19, 2011 | Dec. 31, 2020 | In Use |
00781-5238-64 | 00781-5238 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 31, 2007 | Nov. 30, 2020 | In Use |
00781-5239-01 | 00781-5239 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 13, 2007 | No Longer Used | |
00781-5239-06 | 00781-5239 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 19, 2011 | Dec. 31, 2020 | No Longer Used |
00781-5239-64 | 00781-5239 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 13, 2007 | Dec. 31, 2020 | No Longer Used |
00781-5239-80 | 00781-5239 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 13, 2007 | Oct. 31, 2020 | No Longer Used |
00781-5325-01 | 00781-5325 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Jan. 13, 1998 | In Use | |
00781-5325-31 | 00781-5325 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Jan. 13, 1998 | In Use | |
00781-5356-31 | 00781-5356 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | June 28, 2010 | Nov. 30, 2016 | In Use | |
00781-5409-01 | 00781-5409 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | Dec. 31, 2017 | No Longer Used |
00781-5409-10 | 00781-5409 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | July 6, 2009 | No Longer Used |
00781-5409-31 | 00781-5409 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | Nov. 30, 2017 | No Longer Used |
00781-5409-64 | 00781-5409 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 6, 2009 | Jan. 31, 2015 | No Longer Used |
00781-7152-09 | 00781-7152 | Imiquimod | Imiquimod | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Feb. 28, 2011 | May 31, 2014 | No Longer Used | |
00781-7152-13 | 00781-7152 | Imiquimod | Imiquimod | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Feb. 28, 2011 | May 31, 2014 | No Longer Used | |
00781-9055-12 | 00781-9055 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | July 1, 2023 | In Use | ||
00781-9164-75 | 00781-9164 | Octreotide Acetate | Octreotide Acetate | Hormonal Therapy | Somatostatin Analog | Oct. 21, 1988 | June 29, 2014 | No Longer Used | |||
00781-9165-75 | 00781-9165 | Octreotide Acetate | Octreotide Acetate | Hormonal Therapy | Somatostatin Analog | Oct. 21, 1988 | Nov. 17, 2014 | No Longer Used | |||
00781-9253-94 | 00781-9253 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | March 27, 2014 | Sept. 30, 2024 | In Use |
00781-9315-70 | 00781-9315 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | July 1, 2016 | In Use | |
00781-9317-80 | 00781-9317 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | July 1, 2016 | In Use | |
00832-0086-00 | 00832-0086 | Fluoxymesterone | Androxy | 10.0 mg/1 | Hormonal Therapy | Androgen | Oral | Oct. 21, 1983 | In Use | ||
00832-0285-00 | 00832-0285 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | July 25, 2018 | In Use | |
00832-0532-09 | 00832-0532 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 17, 2024 | In Use |
Found 10,000 results in 5 milliseconds — Export these results